Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit at 11:00 a.m. Eastern Time on Thursday, September 26, 2024.
Neurocrine Biosciences, Inc. (NBIX) stock saw a decline, ending the day at $119.85 which represents a decrease of $-2.46 or -2.01% from the prior close of $122.31. The stock opened at $123 and touched ...
5don MSN
We recently compiled a list of the 10 Best Aggressive Growth Stocks to Buy According to Hedge Funds. In this article, we are ...
Neurocrine Biosciences announced that its ERUDITE Phase 2 trial for luvadaxistat failed to meet its primary endpoint in ...
Neurocrine (NASDAQ:NBIX) Biosciences, Inc. (NASDAQ:NBIX) reported that its Chief Corporate Affairs Officer, David W. Boyer, sold 3,461 shares of the company's common stock on September 13 ...
In this article, we are going to take a look at where Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stands against the other aggressive growth stocks. If you’re putting money in the stock market ...
Sept. 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint steering committee ...
LightPath Technologies, Inc. ("LightPath," the "Company," or "we"), a leading global, vertically integrated provider of thermal imaging cores, custom optical assemblies, photonics and infrared ...
Alkermes plc announced today that management will participate in a fireside chat presentation at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference on Thursday, Sept. 26, 2024 at 9 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback